1. UnitedHealth's stock has fallen 56% in a year, yet insiders and institutional investors are increasing their stakes; 2. Despite disappointing Q2 earnings, new strategic guidance and cost-cutting measures may signal a potential recovery; 3. The author's bearish valuation still projects nearly 30% upside potential for UNH.
Related Articles
- Nvidia Earnings Hysteria: Best Chip Stocks To Buy Now2 months ago
 - 7.5%+ Yield And 12.5% Growth - Buy MPLX's Post Q2 Dip3 months ago
 - Novo Nordisk: Enough Is Enough3 months ago
 - Palantir Q2 Earnings: I'm Dumbfounded, But 110x FCF Is Still Cheap3 months ago
 - Microsoft: Don't Get Too Excited About Future Returns3 months ago
 - Alphabet Is Diving Feet First Into AI Coding4 months ago
 - Verizon Communications Remains A Compelling Value Play4 months ago
 - S&P 500 Earnings: Nothing Much This Week, But Don't Ignore Non-Correlated4 months ago
 - Nvidia Q1 Earnings Review: China Restrictions Getting Worse5 months ago
 - Okta Earnings: Growth Slows, But Financial Strength Stands Out5 months ago